Targeting hypoxia in cancer therapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature Reviews. Cancer

• Publication date

  2011-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc3064PMID 21606941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

  2011cited by this paper
• Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.

  2011cited by this paper
• Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer.

  2011cited by this paper
• Regulation of cancer cell metabolism

  2011cited by this paper
• Potent and Selective Inhibitors of the Inositol-requiring Enzyme 1 Endoribonuclease

  2011cited by this paper
• Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins.

  2011cited by this paper
• Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma.

  2011cited by this paper
• EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.

  2011cited by this paper
• Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer.

  2011cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.

  2011cited by this paper
• EF5 as a predictive biomarker for activation of the new hypoxia-targeting prodrug SN30000.

  2011cited by this paper
• In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection.

  2011cited by this paper
• Hypoxic tumors and their effect on immune cells and cancer therapy.

  2010cited by this paper
• PET of Hypoxia with 89Zr-Labeled cG250-F(ab′)2 in Head and Neck Tumors

  2010cited by this paper
• The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes

  2010cited by this paper
• Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability.

  2010cited by this paper
• Regulation of autophagy by ATF4 in response to severe hypoxia

  2010cited by this paper
• The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

  2010cited by this paper
• Abstract 67: Selective cytotoxic targeting of von Hippel-Lindau-deficient renal cell carcinoma cells

  2010cited by this paper
• Abstract 453: Identification of human oxidoreductases involved in the hypoxia-dependent activation of bioreductive prodrugs

  2010cited by this paper
• Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.

  2010cited by this paper
• Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

  2010cited by this paper
• Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

  2010cited by this paper
• Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

  2010cited by this paper
• Multimodality imaging of hypoxia in preclinical settings.

  2010cited by this paper
• Maintaining genome stability at the replication fork

  2010cited by this paper
• The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5.

  2010cited by this paper
• Targeting Hypoxic Cells through the DNA Damage Response

  2010cited by this paper
• Oxygen-mediated endocytosis in cancer

  2010cited by this paper
• Clinical Cancer esearch cer Therapy : Preclinical rmacokinetic / Pharmacodynamic Modeling Identifies 0000 and SN 29751 as Tirapazamine Analogues with roved Tissue Penetration and Hypoxic R l Killing in Tumors

  2010cited by this paper
• Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

  2010cited by this paper
• Network medicine: a network-based approach to human disease

  2010cited by this paper
• A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

  2010cited by this paper
• Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth.

  2010cited by this paper
• Cancer esearch apeutics , Targets , and Chemical Biology textual Synthetic Lethality of Cancer Cell Kill Based R he Tumor Microenvironment

  2010cited by this paper
• Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.

  2010cited by this paper
• Efficient Hypoxic Activation of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1

  2010cited by this paper
• Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

  2010cited by this paper
• Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis

  2009cited by this paper
• Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia.

  2009cited by this paper
• Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds.

  2009cited by this paper
• The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.

  2009cited by this paper
• Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase.

  2009cited by this paper
• Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia

  2009cited by this paper
• Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours

  2009cited by this paper
• Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

  2009cited by this paper
• Structural Adaptation and Heterogeneity of Normal and Tumor Microvascular Networks

  2009cited by this paper
• Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis

  2009cited by this paper
• Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.

  2009cited by this paper
• Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.

  2009cited by this paper
• Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours

  2009cited by this paper
• Molecular imaging of hypoxia with radiolabelled agents

  2009cited by this paper
• Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia.

  2009cited by this paper
• Design of anticancer prodrugs for reductive activation

  2009cited by this paper
• Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A

  2009cited by this paper
• The HIF-1-active microenvironment: an environmental target for cancer therapy.

  2009cited by this paper
• Hypoxia-induced Expression of Carbonic Anhydrase 9 Is Dependent on the Unfolded Protein Response*

  2009cited by this paper
• Cancer stem cells, hypoxia and metastasis.

  2009cited by this paper
• Targeting the hypoxia-inducible factor (HIF) pathway in cancer

  2009cited by this paper
• Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies

  2009cited by this paper
• Regulation of autophagy through multiple independent hypoxic signaling pathways.

  2009cited by this paper
• Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer

  2009cited by this paper
• AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7–10

  2009cited by this paper
• Abstract B76: Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia‐activated irreversible pan‐HER inhibitor

  2009cited by this paper
• Tumor hypoxia as a modifier of DNA strand break and cross-link repair.

  2009cited by this paper
• HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms.

  2009cited by this paper
• Hypoxia signalling through mTOR and the unfolded protein response in cancer

  2008cited by this paper
• Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase.

  2008cited by this paper
• Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

  2008cited by this paper
• Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.

  2008cited by this paper
• Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.

  2008cited by this paper
• Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability

  2008cited by this paper
• A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death

  2008cited by this paper
• Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.

  2008cited by this paper
• Prediction of Tumour Tissue Diffusion Coefficients of Hypoxia-Activated Prodrugs from Physicochemical Parameters

  2008cited by this paper
• Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

  2008cited by this paper
• Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice.

  2008cited by this paper
• DNA repair pathways as targets for cancer therapy

  2008cited by this paper
• Dissecting the Role of Multiple Reductases in Bioactivation and Cytotoxicity of the Antitumor Agent 2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1)

  2008cited by this paper
• 18F-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck Cancer

  2008cited by this paper
• Hypoxia, DNA repair and genetic instability

  2008cited by this paper
• Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases.

  2008cited by this paper
• Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells.

  2008cited by this paper
• Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing.

  2008cited by this paper
• Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards

  2007cited by this paper
• Targeting hypoxia cell signaling for cancer therapy

  2007cited by this paper
• Detection of Reactive Oxygen Species via Endogenous Oxidative Pentose Phosphate Cycle Activity in Response to Oxygen Concentration

  2007cited by this paper
• Bnip3 Mediates the Hypoxia-induced Inhibition on Mammalian Target of Rapamycin by Interacting with Rheb*

  2007cited by this paper
• Detection and Characterization of Tumor Hypoxia Using pO2 Histography

  2007cited by this paper
• Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.

  2007cited by this paper
• Differential Toxic Mechanisms of 2-Deoxy-D-Glucose versus 2-Fluorodeoxy-D -Glucose in Hypoxic and Normoxic Tumor Cells

  2007cited by this paper
• Chemical radiosensitizers for use in radiotherapy.

  2007cited by this paper
• Targeting tumors with hypoxia-activated cytotoxins.

  2007cited by this paper
• Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression

  2007cited by this paper
• Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.

  2007cited by this paper
• DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).

  2007cited by this paper
• In vivo role of NAD(P)H:quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity.

  2007cited by this paper
• Evaluation of HIF-1 inhibitors as anticancer agents.

  2007cited by this paper
• Synthetic lethal screen identification of chemosensitizer loci in cancer cells

  2007cited by this paper
• Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor.

  2007cited by this paper

• Development of a Novel Approach for In Vivo Tumor Hypoxia PET Imaging with Nitroreductase-Specific Responsive Radiotracers.

  2026cites this paper
• Beyond the chaos: How architecture structures tumour biology.

  2026cites this paper
• Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.

  2026cites this paper
• Smart hypoxia-responsive sulfated polysaccharides liposomes for controlled and targeted urokinase delivery in thrombotic therapy.

  2026cites this paper
• Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion

  2026cites this paper
• A nanoengineered strategy combining deep oxygenation and immunogenicity regulation to unleash the power of anti-tumor immunity

  2026cites this paper
• X-ray activated platinum complex induces DNA damage and enhances cancer immunotherapy through abscopal effect.

  2026cites this paper
• A mechanical reprogramming: synergistic tumor microenvironment normalization improves nano-immunotherapy delivery in prostate cancer via multiphysics modeling.

  2026cites this paper
• Advances in cancer biomarkers: current detection strategies and challenges

  2026cites this paper
• Tumor-Selective and Chemical Activation Strategies for Nitrogen Mustard Prodrugs.

  2026cites this paper
• Systemic CYP3A inhibition by ritonavir enables selective targeting of hypoxic tumour cells by prodrugs of DNA-PK inhibitors

  2026cites this paper
• Multi-functional engineered metal-based singlet oxygen battery: Photo-controlled singlet oxygen release and prodrug activation for hypoxic tumor therapy

  2026cites this paper
• Targeted drug delivery strategies for oral cancer: the role of liposomes in drug delivery systems

  2026cites this paper
• Epigenetic Metal‐Organic Framework Nanoagonist Overcomes Triple Defenses to Enable Effective Chemo‐Metalloimmunotherapy in Platinum‐Resistant Ovarian Cancer

  2026cites this paper
• Chemiluminescence‐Powered Immunotherapy for Deep Tumors: Promoting PD‐L1 Degradation and Igniting Pyroptosis Through Subcellular Trafficking and Targeting

  2026cites this paper
• Emerging Development of Microalgae-Containing Biomaterials for Biomedical Applications

  2026cites this paper
• Combined experimental and computational investigation of a novel naphthalene-based VEGFR-2 inhibitor with nonlinear optical activity

  2026cites this paper
• Engineering Mesenchymal Stem Cells with Nanomaterials for Tumor Microenvironment Regulation and Precision Therapy.

  2026cites this paper
• Impeding the NHEJ Pathway for Overcoming Radioresistance in the Context of Precision Radiotherapy of Cancer

  2026cites this paper
• Hypoxia-Activated NIR-II Fluorescent Probes for Breast Tumor Imaging via N -Oxide BF 2 Formazanate Scaffolds

  2026cites this paper
• Stimuli‐Responsive Supramolecular Biomaterials for Cancer Theranostics

  2026cites this paper
• Rational modification of PROTACs for tumor-selective protein degradation.

  2026cites this paper
• Advances in targeted therapies by PARP inhibitors for the treatment of prostate cancer: A scientometric approach

  2025cites this paper
• Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors

  2025cites this paper
• Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives

  2025cites this paper
• Correlation Between MRI Characteristic of Osteosarcoma with 2-Year Survival Outcomes

  2025cites this paper
• Hypoxia and immunometabolism in the tumor microenvironment: insights into mechanisms and therapeutic potential.

  2025cites this paper
• Discovery of novel thiourea benzenesulfonamides based 1,8-naphthalimide derivatives as carbonic anhydrase IX inhibitors that induce ferroptosis and inhibit triple-negative breast cancer metastasis

  2025cites this paper
• Resynthesis of synthetic biology techniques: combining engineered bacteria with other antitumour therapies

  2025cites this paper
• Profiling of RUVBL2‐Induced Transcriptome Alterations Highlights a Critical Role for Chromatin Remodeling in Ovarian Cancer

  2025cites this paper
• Ultrasmall polylysine dendrimer nanodots for glutathione-responsive targeted chemotherapy and enhanced photodynamic/immunotherapy of metastatic cancer

  2025cites this paper
• Optimization of HAP administration in cancer therapy

  2025cites this paper
• Fibre, microbes and radiotherapy: unravelling the gut’s impact on radiotherapy in cancer

  2025cites this paper
• Hypoxia-sensitive macrocycle inclusion complexes for targeted protein degradation.

  2025cites this paper
• TH-302 (evofosfamide) monotherapy exerts anticancer activity in Ewing's sarcoma cells under hypoxia

  2025cites this paper
• Dual-phoretic wireless device for directionally oriented and carrier-free targeted drug delivery

  2025cites this paper
• Branched‐Chain α Keto‐Acid Dehydrogenase Kinase‐Mediated AKT Phosphorylation Promotes RCC Tumorigenesis and Drug Resistance

  2025cites this paper
• Kaempferol promotes apoptosis and inhibits proliferation and migration by suppressing HIF-1α/VEGF and Wnt/β-catenin activation under hypoxic condition in colon cancer

  2025cites this paper
• Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application

  2025cites this paper
• Developing bioinspired delivery systems for enhanced tumor penetration of macromolecular drugs.

  2025cites this paper
• Nanotherapeutic strategies exploiting biological traits of cancer stem cells

  2025cites this paper
• Mechanical Forces in Tumor Growth and Treatment: Perspectives From Biology, Physics, Engineering, and Mathematical Modeling.

  2025cites this paper
• Oxygen targets in critically ill patients: from pathophysiology to population enrichment strategies

  2025cites this paper
• Hydrogen radical-based prodrug photoactivation by modulating bond dissociation energy of a phenolic photosensitizer

  2025cites this paper
• Hypoxia-related gene DDIT4 as a therapeutic biomarker promotes epithelial-mesenchymal transition in lung adenocarcinoma via the MAPK/ERK signaling pathway.

  2025cites this paper
• The synergistic potential of mechanotherapy and sonopermeation to enhance cancer treatment effectiveness

  2025cites this paper
• Multi-model quantitative MRI of uterine cancers in precision medicine’s era—a narrative review

  2025cites this paper
• Prognostic value of immunohistochemical markers of intratumoral hypoxia in pregnancy-associated breast cancer

  2025cites this paper
• A hypoxia-activated copper ion nanoexchanger for cancer immunotherapy by in situ precise production of immunogenic cell death inducer

  2025cites this paper
• Tumor microenvironment and immunotherapy: from bench to bedside

  2025cites this paper
• Electron-pump-like near-infrared emissive iridium(III) complexes for hypoxia-tolerant type I & II photodynamic therapy

  2025cites this paper
• Hypoxia-elicited exosomal HIF-1α promotes drug resistance of melanoma through modulating SLC7A11 ubiquitination.

  2025cites this paper
• Near-infrared II nanomaterials for hypoxic TME diagnosis and therapy.

  2025cites this paper
• Biodegradable MnO2-x sensitized hollow prussian blue for enhanced sono-immunotherapy through cascade amplification of ROS generation and activation of cGAS-STING pathway

  2025cites this paper
• A promising platform of hypoxia sensitive magnetosomes in hepatocellular carcinoma therapy

  2025cites this paper
• Bismuth-functionalized probiotics for enhanced antitumor radiotherapy and immune activation.

  2025cites this paper
• Single-cell sequencing revealed the recurrence causes of ETV6::RUNX1 fusion-positive B-ALL in children.

  2025cites this paper
• Mathematical modeling and sensitivity analysis of hypoxia-activated drugs

  2025cites this paper
• Hypoxia facilitates stemness of colon cancer cells via histone lactylation.

  2025cites this paper
• A hypoxia-leveraged near-IR theranostic nanomedicine enables imaging-guided tumor diagnosis and photothermal therapy.

  2025cites this paper
• Targeted Delivery of Rapamycin via Epidermal Growth Factor Receptors in Pancreatic Cancer Cells Inhibits Cell Proliferation and Induces Apoptosis

  2025influential citation
• Navigating the future of oncology: the transformative role of microrobots in precision cancer therapy.

  2025cites this paper
• ATP-Assisted Electron and Proton Transfer Boosting Redox Metabolism-Induced Ferroptosis and Apoptosis for Cancer Therapy.

  2025cites this paper
• The mechanopathology of the tumor microenvironment: detection techniques, molecular mechanisms and therapeutic opportunities

  2025cites this paper
• Dissection of tumoral niches using spatial transcriptomics and deep learning

  2025cites this paper
• Photoinduced Synergism of Ferroptosis/Pyroptosis/Oncosis by an O2-Independent Photocatalyst for Enhanced Tumor Immunotherapy.

  2025cites this paper
• Antitumor effects of dauricine on sorafenib-treated human lung cancer cell lines via modulation of HIF-1α signaling pathways

  2025cites this paper
• Tumor Microenvironment-Responsive Proteolytic Nanodrug against Breast Cancer

  2025cites this paper
• Sensitizing ferroptotic and apoptotic cancer therapy via tailored micelles-mediated coenzyme and ATP depletion under hypoxia.

  2025cites this paper
• Coenzyme Q10 as an Inhibitor of Effector Release from One-Electron-Reduced Bioreductive Anticancer Prodrugs

  2025influential citation
• A Universal Single-Activated-Dual-Release Vehicle: Enabling Synergistic Antitumor Therapy.

  2025cites this paper
• Hypoxia-responsive bilirubin supramolecular nanoprodrugs for targeted photothermal-chemotherapy.

  2025cites this paper
• Applications and enhancement strategies of ROS-based non-invasive therapies in cancer treatment

  2025cites this paper
• Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures

  2025cites this paper
• Development of a near-infrared fluorescent probe for the selective detection of severe hypoxia

  2025cites this paper
• Subcellular Organelle Targeting as a Novel Approach to Combat Tumor Metastasis

  2025cites this paper
• Synchronous Dual-Cycle Amplification System Based on Programmable Ago-DNA Polymerase for Detecting Tumor-Related MicroRNAs.

  2025cites this paper
• Overcoming multifaceted challenges in cancer treatment: Targeting signal transduction pathways and tumor microenvironment for enhanced therapeutic efficacy

  2025cites this paper
• ROS-ATM-CHK2 axis stabilizes HIF-1α and promotes tumor angiogenesis in hypoxic microenvironment

  2025cites this paper
• Engineering exosome membrane disguised thermal responsive system for targeted drug delivery and controlled release across the blood-brain barrier

  2025cites this paper
• Ultrasound-Activated Theranostic Materials and their Bioapplications.

  2025cites this paper
• 5-Aminolaevulinic Acid-Mediated Photodynamic Therapy Combined with Tirapazamine Enhances Efficacy in Ovarian Cancer

  2025cites this paper
• A Review of Metabolic Reprogramming in Cancer

  2025cites this paper
• The solid tumor microenvironment and related targeting strategies: a concise review

  2025cites this paper
• Evodiamine-Based Nitroreductase Responsive Theranostic Agents for Treatment of Colon Cancer.

  2025cites this paper
• The cost-efficient techniques to evaluate the age-based structural heterogeneity and morphological analysis of multicellular tumor spheroids.

  2025cites this paper
• Binuclear Lanthanide Complexes as Magnetic Resonance and Optical Imaging Probes for Redox Sensing

  2025cites this paper
• Integrative Multi-omics and Supervised Learning Identifies an Epithelial Signature for Radiotherapy Response in Colorectal Cancer

  2025cites this paper
• Hypoxia and Viscosity Co-Controlled Fluorescence Probe for Signal Amplification Imaging of Early Hypoxia-Related Diseases

  2025cites this paper
• Camouflaged Nanozymes with Oxidation‐Promoting Activities Triggering Ferroptosis for Radio‐Immunotherapy

  2025cites this paper
• Reprogramming of radiation-deteriorated TME by liposomal nanomedicine to potentiate radio-immunotherapy.

  2025cites this paper
• Engineering TME-gated inducible CAR-T cell therapy for solid tumors.

  2025cites this paper
• Emerging Multifunctional Biomaterials for Addressing Drug Resistance in Cancer

  2025cites this paper
• Strategy‐Level Prodrug Synthesis

  2025cites this paper
• A hypoxia-responsive liquid metal-containing nanomaterial for cancer phototheranostics.

  2025cites this paper
• Oncolytic virus therapy through mathematical modeling: the infection-lysis trade-off in cancer dynamics

  2025cites this paper
• Nitroreductase-Responsive Bioorthogonal Tetrazine Conjugations in Cancer Cells.

  2025cites this paper
• Advancements in Nanocarrier Delivery Systems for Photodynamic Therapy in Lung Cancer

  2025influential citation
• Hyperpolarized [1-13C]pyruvate NMR spectroscopy reveals transition of tumor energy metabolism in microscale multicellular spheroids

  2025cites this paper
• Difunctional oxidatively cleavable alkenyl boronates: application to cellular peroxide sensing from a fluorophore–quencher pair

  2025cites this paper